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doi: 10.1016/j.bpj.2010.09.015Alzheimer’s disease, a fatal neurodegenerative disorder of
the elderly, is characterized by extracellular depositions of
amyloid-b peptide (Ab) saturated with metal ions (1). It is
believed that Zn2þ ions play a key role in pathological
aggregation of Ab and therefore affect the pathogenesis of
Alzheimer’s disease (2–5). The amino acid region 1–16
(Ab(1–16)) is generally considered as the metal binding
domain of Ab (6). N-acetylated and C-amidated peptide
Ab(1–16) is soluble and stable in the presence of zinc
ions under physiological conditions (7), and the three-
dimensional structures of this domain in Zn2þ-loaded and
Zn2þ-free states have been solved by NMR (8). In the
Zn2þ-Ab(1–16) complex, zinc is tetrahedrally coordinated
to His6, His13, and His14 through their N-d1, N-32, and
N-d1 atoms, respectively, and to Glu11 through its O-d atom.
At the same time, several alternative coordination modes
of zinc binding to Ab with nonacetylated N-terminus are
discussed (6,9). While there is general agreement regarding
the participation of the three histidine residues, the role of
Asp1 as fourth zinc chelator instead of Glu11 has been
proposed (10). In addition, a pentacoordination of zinc ion
by Asp1, His6, Glu11, His13, and His14 has been also sug-
gested (11). However, in contrast to the data published by
Zirah et al. (8), none of the alternative complexes has
been defined structurally. Thus, the exact mode of zinc coor-
dination by Ab deserves further investigation.
In this work, we characterize the thermodynamics of the
binding of Zn2þ to Ab fragments and Ab(1–16) mutants by
isothermal titration calorimetry (ITC) in order to determine
the minimal Zn2þ-binding site of Ab under physiological
conditions. We also use the quantum mechanics/molecular
mechanics (QM/MM) method to model Zn2þ recognition
by Ab.
Thermodynamic parameters of Zn2þ binding to Ab frag-
ments and Ab(1–16) mutants obtained by ITC (Fig. 1 and
Fig. S1 in the Supporting Material) are presented in Table 1.It can be seen that acetylation of N-terminus does not
dramatically change Zn2þ binding to Ab(1–16).
The truncation of five amino acids from the N-terminal
part and two from the C-terminus of Ab(1–16) leads to
the fivefold increase in its affinity to Zn2þ (Fig. 1, Table 1).
This could be explained by the formation of a hydrogen
bond between His6 and either Asp1 or Glu3 in Ab(1–16)
in the absence of zinc (Fig. S2). At the same time, titration
of the Ab(1–5) fragment with Zn2þ ions did not produce any
heat. It is important to note that angiotensin-converting
enzyme proteolytically cleaves this fragment from Ab (12).
Thus, angiotensin-converting enzyme can increase zinc
affinity to Ab and act as a modulator of zinc binding. Visible
aggregation of Ab(6–14) peptide was observed in the calori-
metrical cell upon interaction with zinc. However, this
aggregation does not affect stoichiometry of Zn2þ binding
(Table 1), suggesting that formation of oligomers occurs not
via Zn2þ ions, but through interpeptide interactions of
Zn2þ-loaded Ab(6–14) in the same manner as for Ab which
first binds to zinc and then is conformationally driven to
aggregates (13). Further removing of one of the terminal histi-
dines fromAb(6–14) results in the remarkable drop in associ-
ation constant Ka from 8.6  104 M1 to 1.7  103 M1 for
peptideAb(7–14) and to 3.4 103M1 for peptideAb(6–13).
These data indicate that all Zn2þ-chelating amino acids
are located within the Ab(6–14) peptide and that the Ab
(1–5) segment of Ab is not necessary for Zn2þ binding.
Amino acids located between Asp7 and Tyr10 of Ab do
not participate in Zn2þ binding, because their removal
(Ab(7–14)/ Ab(11–14)) only slightly changes the affinity
of the peptide to zinc. Substitution of Glu11 to Ala as well as
FIGURE 1 ITC titration curves (upper panel) and binding
isotherms (lower panel) for zinc interactions with Ab(1–16), Ab
(6–14), and Ab(6–13) (black, red, and blue curves, respectively)
at 25C in 50 mM Tris buffer, pH 7.3.
Biophysical Letters L85His6 to Arg in Ab(1–16) causes strong decrease of Zn2þ
affinity (Table 1). These data clearly demonstrate that
His6, Glu11, and His14 are necessary for Zn2þ coordination,
which is in good agreement with NMR structural data (8).
Zinc binding to all studied Ab fragments and Ab(1–16)
mutants was enthalpy-driven (Table 1). Contrary to the Ab
(1–16) domain, Zn2þ binding to Ab(6–14), Ab(7–14), and
Ab(6–13) peptides was entropically unfavorable. This is
explained by burying hydrophobic surfaces upon Zn2þ
binding to Ab(1–16), which is in line with the structuralTABLE 1 Thermodynamic parameters of Zn2þ ions binding to
Ab fragments and Ab(1–16) mutants obtained by ITC at 25C in
50 mM Tris buffer, pH 7.3
Peptide* Ny
Ka
x DHy TDS
(M1  104) (kcal M1) (kcal M1)
Ab(1–16) 1.1 1.80 4.0 1.8
NH2-Ab(1–16) 1.1 3.90 5.4 0.9
Ab(6–14) 1.0 8.60 9.2 2.5
Ab(6–13) 0.6 0.34{ 8.1 3.3
Ab(7–14) 0.9 0.17 7.9 3.5
Ab(11–14) 0.5 0.27{ 2.6 2.1
Ab(1–5) No binding
Ab(1–16) H6R 0.8 0.25 6.4 1.8
Ab(1–16) E11A 1.0 0.54 6.9 1.8
All experiments were carried out on an iTC200 instrument (MicroCal,
Northampton, MA).
*All peptides were purchased from Biopeptide (San Diego, CA). The N- and
C-termini of each peptide were protected with acetyl and amide, respec-
tively; peptide NH2-Ab(1–16) was protected at the C-terminus with amide.
yStandard deviation did not exceed510%.
xStandard deviation did not exceed520%.
{Due to peptide dimerization, Ka dimension is equal to M
2.data (8). Stoichiometry of Zn2þ binding to Ab(6–13) and
Ab(11–14) fragments is close to 0.5 (Table 1), indicating
dimer formation via Zn2þ ion which is in a good agreement
with a recent simulation study (14). High positive entropy of
Zn2þ binding to Ab(11–14) dimer is explained by formation
of hydrophobic contacts between the two subunits.
This is also confirmed by an NMR study of the Zn2þ-Ab
(11–14) dimer. 1H NMR spectra (Fig. S3) demonstrate that
resonance peaks of both valine methyl groups are strongly
upshifted upon Zn2þ binding to Ab(11–14) (from 0.83 and
0.75 to 0.45 and 0.69 ppm), due to the proximity of the
zinc ion. The peak that displays the stronger shift undergoes
significant broadening, also indicating that the correspond-
ing methyl group is very close to Zn2þ. The coordination
of Zn2þ by two peptide molecules resulting in the formation
of a symmetrical complex is in good agreement with NMR
data as well. In such a complex, valine methyl groups within
the immediate neighborhood of Zn2þ ion are oriented
inward, which means that they are not exposed considerably
to the solution.
Thus, we propose that the tetrapeptide Ab(11–14) con-
taining three Zn2þ chelating amino acids functions as a
Zn2þ recognition site. In line with this hypothesis, NMR
data demonstrate that this site has a definite structure in
the absence of Zn2þ (8). We suppose that Zn2þ capture by
the structured EVHH region is the initial step in the forma-
tion of the Zn2þ-Ab(1–16) complex.
The dimerization of the Ab(11–14) peptide upon Zn2þ
binding makes it impossible to determine the thermody-
namic parameters of binding for the monomeric peptide,
i.e., to reveal the role of this fragment in the mechanism
of Zn2þ recognition by Ab in more detail. Therefore, we
applied an approach similar to that described by Furlan
and La Penna (15). Theoretical calculations of the stability
of a transitional EVHH complex with zinc were performed.
QM/MM simulations were applied to analyze Zn2þ binding
by Ab(11–14), Ab(6–14), and Ab(1–16) peptides. Starting
conformation for each peptide complexed with Zn2þ was
derived from the Ab(1–16) structure (PDB ID: 1ZE9).
Simulations showed that both Ab(6–14) and Ab(1–16)
peptides where Zn2þ was chelated by His6, Glu11, His13,
and His14 kept stable tetrahedral coordination of zinc during
8 ps of the QM/MM simulation trajectory. In the case of Ab
(6–14) energy, the QM part (see the Supporting Material for
details) was slightly smaller because His13 is better oriented
in the complex (Table 2). For Ab(11–14), fast (1-ps) forma-
tion of the tetrahedral Zn2þ coordination environment
(Table 2) with a water molecule as the fourth chelator was
observed (see Movie S1 in the Supporting Material). In
the longer (8-ps) simulation, this water molecule was stable
in terms of orientation and position. Summarizing our simu-
lation results, we conclude that initially Zn2þ is recognized
and captured by the EVHH region of Ab and temporarily
coordinated by water as the fourth chelator (Fig. 2 A).
This state exists until His6 comes close to Zn2þ due toBiophysical Journal 99(10) L84–L86
TABLE 2 Energy and geometry values of zinc coordination by
Ab(1–16), Ab(6–14), and Ab(11–14) peptides obtained by QM/
MM simulations
Ab(1–16) Ab(6–14) Ab(11–14)
Energy of QM subsystem, kJ/mol
6185715 27 6186215 64 NA
Distance, nm
Zn2þ/ His6 (Nd) 0.2025 0.006 0.2035 0.005 0.2065 0.010
Zn2þ/ H2O (O) NA NA 0.2065 0.010
Zn2þ/ Glu11 (Od) 0.2205 0.014 0.2265 0.015 0.2005 0.007
Zn2þ/ His13 (N3) 0.2075 0.006 0.2075 0.006 0.2025 0.007
Zn2þ/ His14 (Nd) 0.2095 0.006 0.2095 0.006 0.1995 0.006
Angle, degrees
His6-Zn2þ-Glu11 96.55 4.6 95.65 5.2 NA
His6-Zn2þ-His13 131.05 3.7 134.25 4.2 NA
His6-Zn2þ-His14 110.85 4.2 110.45 4.6 NA
Glu11-Zn2þ-His13 85.25 4.5 83.05 3.2 98.15 6.1
Glu11-Zn2þ-His14 96.35 4.6 96.95 5.2 112.65 7.0
His13-Zn2þ-His14 117.05 5.2 114.05 4.2 116.55 5.7
H2O-Zn
2þ-Glu11 NA NA 97.55 6.9
H2O-Zn
2þ-His13 NA NA 111.95 8.0
H2O-Zn
2þ-His14 NA NA 115.55 7.9
NA: not applicable.
L86 Biophysical Lettersthermal fluctuations and replaces the water molecule in the
zinc coordination environment, resulting in the formation of
the final complex (Fig. 2 B).
In summary, we used ITC to characterize the interactions
of Zn2þwith fragments of native Ab and Ab(1–16) mutants.
The amino acid region 6–14 of Ab was determined as the
minimal Zn2þ-binding site wherein the ion is coordinated
by His6, Glu11, His13, and His14. Both ITC and QM/MM
showed that three of four residues from the Ab region
11–14 (EVHH) contribute to zinc binding, and that this tet-
rapeptide readily forms dimers linked through a zinc ion,
similarly to a model proposed for Ab aggregation in a recent
molecular dynamics study (14).
These data allow us to consider Ab(11–14) tetrapeptide as
a primary Zn2þ-recognition site of Ab and an important drug
target candidate to prevent Zn2þ-induced aggregation of Ab.FIGURE 2 Schema of Zn2þ ion recognition by the Ab binding
site 6–14 according to QM/MM calculations performed with the
GROMACS/CPMD package (http://www.tougaloo.edu/research/
qmmm/index.htm) based on PDB ID: 1ZE9. (A) structure of the
intermediate Zn2þ-Ab complex with a water molecule as the
fourth chelator; (B) structure of the final Zn2þ-Ab complex. See
also Movie S2 in the Supporting Material.
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